News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
NFATC2 Variation Linked to Rosiglitazone-induced Edema
October 4, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MedWire News: Variation in the NFATC2 (nuclear factor of activated T-cells cytoplasmic calcineurin-dependent 2) gene is associated with increased risk for rosiglitazone-associated edema, show results from a subanalysis of the DREAM trial.
Twitter
LinkedIn
Facebook
Email
Print